We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s ...

Viking Therapeutics (VKTX) shares crashed nearly 29% in today’s trade after the company’s much-anticipated weight-loss pill ...

Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral ...

The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli ...

Viking shares fell on Phase 2 obesity pill data as tolerability issues surfaced, but William Blair says the stock's sell-off ...

Viking Therapeutics (NASDAQ:VKTX) stock plunged as much as 37% Tuesday after revealing results from its Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment, while Eli Lilly (NYSE:LLY) ...

Viking Therapeutics (VKTX) stock drops as its oral obesity drug VK2735 trails Novo's (NVO) oral Wegovy and Lilly's (LLY) ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra ...

Viking Therapeutics stock plunges 37% as trial data sparks concerns over dropout rates and side effects despite weight loss ...

Viking Therapeutics reported positive Phase 2 results for VK2735, showing significant weight loss and safety in obesity ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE ...

The clinical-stage biopharmaceutical firm, Viking Therapeutics, Inc. (NASDAQ:VKTX), based in San Diego, develops novel ...